Introduction
Bioidentical hormone replacement therapy (BHRT) for women represents one of the fastest-growing areas of hormone medicine, driven by the estimated 6,000 women who enter menopause every day in the United States. Yet BHRT remains controversial in some medical circles, underserved in conventional healthcare, and filled with marketing claims that outpace the evidence. For practitioners building a women’s hormone therapy practice, developing evidence-based BHRT protocols is both a clinical imperative and a competitive differentiator.
Understanding the BHRT Landscape
BHRT refers to hormone therapy using hormones that are chemically identical to those produced by the human body—primarily estradiol, progesterone, and testosterone. BHRT can be delivered through FDA-approved commercial products (patches, gels, oral micronized progesterone) or through compounded formulations from licensed compounding pharmacies. Understanding which options are FDA-approved and which are compounded is essential for patient counseling and legal compliance.
Patient Evaluation for BHRT
A thorough evaluation before initiating BHRT includes: comprehensive history (menstrual history, menopausal symptoms, cardiovascular risk factors, personal and family history of breast and uterine cancer), physical examination including breast and pelvic exam, and laboratory assessment. Standard labs include FSH, estradiol, progesterone, testosterone (total and free), SHBG, DHEA-S, cortisol, thyroid panel, CBC, CMP, and fasting lipids.
The Role of Estrogen in BHRT
Estrogen is the primary hormone used to treat menopausal symptoms. Transdermal estradiol (patches, gels, sprays) is preferred over oral estrogen for most women due to lower risk of venous thromboembolism and more favorable metabolic effects. Vaginal estrogen is appropriate for genitourinary symptoms (vaginal atrophy, dryness, urinary urgency) and is generally safe even for women with a history of breast cancer when local and low-dose.
Progesterone: Protecting the Uterus and Beyond
Any woman with an intact uterus receiving systemic estrogen must also receive progestogen to protect against endometrial hyperplasia and cancer. Oral micronized progesterone (Prometrium) is the preferred form in most evidence-based protocols due to its favorable safety profile compared to synthetic progestins. Compounded progesterone creams have inconsistent absorption and are generally not recommended for endometrial protection.
Testosterone in Women’s BHRT
Testosterone therapy for women—while not FDA-approved for this indication—has growing evidence for improving libido, energy, mood, and cognitive function in postmenopausal women. Dosing is typically 1/10th of male doses (1-5mg/day transdermally). Monitoring includes baseline and follow-up testosterone and SHBG levels, along with symptom assessment.
Monitoring and Follow-Up
BHRT patients require regular monitoring: symptom review at 4-8 weeks after initiation, lab assessment at 3 months, and annual mammography, bone density screening, and cardiovascular risk assessment. Adjust doses based on symptoms and lab values, not lab values alone.
Conclusion
BHRT for women offers tremendous opportunity to alleviate suffering and improve quality of life for millions of women navigating perimenopause and menopause. With sound protocols, thorough evaluation, and evidence-based prescribing, your hormone therapy practice can become a trusted resource for women seeking comprehensive hormonal care.